Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PET Scan with PF-03654746 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | This arm will have no active treatment. |
| Cohort 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Positron Emission tomography | OTHER | Positron Emission tomography scans. Part 1of the study : 4 subjects will receive 2 scans a day for 1 day with PET ligand administered in tracer quantities. |
| PET Scan with PF-03654746 | DRUG | If none of the data from Cohort 2 is informative, then: 2) an additional 3 subjects will receive 2 Scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746. Doses will be determined based upon the outcome of the first intervention. |
Inclusion Criteria: * Healthy male subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical l...
PET Scan with PF-03654746 is an investigational small molecule being studied in healthy volunteers. It is used in positron emission tomography (PET) imaging to visualize and measure the distribution of PF-03654746 in the body. The drug is in Phase 1 clinical development.
PET Scan with PF-03654746 is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting clinical trials to evaluate the drug's properties in healthy volunteers.
PET Scan with PF-03654746 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 study has been completed.
PET Scan with PF-03654746 is associated with one completed Phase 1 clinical trial, NCT00730990, titled "A Phase I, Healthy Volunteer Positron Emission Tomography Study." The trial enrolled 10 healthy male participants in the United States.
PET Scan with PF-03654746 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed Phase 1 trial was a controlled study in healthy volunteers.